INPEFA. SOTAGLIFLOZIN TABLETS

Serial Number 97653516
Registration 7141092
700

Registration Progress

Application Filed
Oct 28, 2022
Under Examination
Mar 21, 2023
Approved for Publication
Jan 24, 2023
Published for Opposition
Jan 24, 2023
Registered
Aug 15, 2023

Trademark Image

INPEFA. SOTAGLIFLOZIN TABLETS

Basic Information

Serial Number
97653516
Registration Number
7141092
Filing Date
October 28, 2022
Registration Date
August 15, 2023
Published for Opposition
January 24, 2023
Drawing Code
5

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 15, 2023
Registration
Registered
Classes
005

Rights Holder

Lexicon Pharmaceuticals, Inc.

03
Address
2445 Technology Forest Blvd., Suite 1100
The Woodlands, TX 77381

Ownership History

Lexicon Pharmaceuticals, Inc.

Original Applicant
03
The Woodlands, TX

Lexicon Pharmaceuticals, Inc.

Owner at Publication
03
The Woodlands, TX

Lexicon Pharmaceuticals, Inc.

Original Registrant
03
The Woodlands, TX

Legal Representation

Attorney
Tania Shapiro-Barr

USPTO Deadlines

Next Deadline
1331 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20230815)
Due Date
August 15, 2029
Grace Period Ends
February 15, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

30 events
Date Code Type Description Documents
Apr 14, 2025 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Apr 14, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Apr 14, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Apr 14, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Aug 15, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Aug 15, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jul 11, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jul 10, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jun 17, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 16, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jun 8, 2023 IUAF S USE AMENDMENT FILED Loading...
Jun 16, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jun 8, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 16, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 8, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 8, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Mar 21, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 24, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 24, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 4, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 21, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 7, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 7, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 7, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 6, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 6, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 6, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 29, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 15, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 1, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment or prevention of heart failure
First Use Anywhere: May 18, 2023
First Use in Commerce: May 18, 2023

Additional Information

Design Mark
The mark consists of stlylized phrase "inpefa. sotagliflozin tablets".
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TABLETS"